Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

doi:10.1158/2159-8290.CD-14-1236

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

Cancer discovery - 1 Aug 2015

Skoulidis Ferdinandos, Byers Lauren A, Diao Lixia, Papadimitrakopoulou Vassiliki A, Tong Pan, Izzo Julie, Behrens Carmen, Kadara Humam, Parra Edwin R, Canales Jaime Rodriguez, Zhang Jianjun, Giri Uma, Gudikote Jayanthi, Cortez Maria A, Yang Chao, Fan Youhong, Peyton Michael, Girard Luc, Coombes Kevin R, Toniatti Carlo, Heffernan Timothy P, Choi Murim, Frampton Garrett M, Miller Vincent, Weinstein John N, Herbst Roy S, Wong Kwok-Kin, Zhang Jianhua, Sharma Padmanee, Mills Gordon B, Hong Waun K, Minna John D, Allison James P, Futreal Andrew, Wang Jing, Wistuba Ignacio I, Heymach John V

Abstract excerpt

UNLABELLED: The molecular underpinnings that drive the heterogeneity of KRAS-mutant lung adenocarcinoma are poorly characterized. We performed an integrative analysis of genomic, transcriptomic, and proteomic data from early-stage and chemorefractory lung adenocarcinoma and identified three robust subsets of KRAS-mutant lung adenocarcinoma dominated, respectively, by co-occurring genetic events in STK11/LKB1 (the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Adenocarcinoma of Lung

Share to AMP-Activated Protein Kinase Kinases

Share to AMP-Activated Protein Kinases

Share to Inflammation

Share to Oxidative Stress

Share to ras Proteins

Share to Tumor Suppressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 26069186
DOI: 10.1158/2159-8290.CD-14-1236
PMCID: PMC4527963

Genes

KRAS
STK11
TTF1
KEAP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.PMID 26069186Read ↗

Distinct molecular subtypes of KRASG12C-mutant lung adenocarcinoma: Insights into clinical outcomes, tumour microenvironments and therapeutic strategies.Semantic proximity Read ↗

Prevalence and clinico-morphological correlates of STK11 mutations in a large cohort of NSCLC lung adenocarcinomas.Semantic proximity Read ↗

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomasSemantic proximity Read ↗

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.Semantic proximity Read ↗

The landscape of responses to neoadjuvant immunotherapy in resectable Kirsten rat sarcoma viral oncogene homolog-mutant lung adenocarcinoma: Clinical heterogeneity and correlative immunologic analysis.Semantic proximity Read ↗

Clinical significance of concurrent TP53 mutations in KRAS-mutant invasive mucinous adenocarcinoma patients undergoing curative-intent lung surgery.Semantic proximity Read ↗

A Critical Review of the Prognostic and Predictive Implications of KRAS and STK11 Mutations and Co-Mutations in Metastatic Non-Small Lung CancerSemantic proximity Read ↗

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.Semantic proximity Read ↗

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.Semantic proximity Read ↗

Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on KRAS G12C.Semantic proximity Read ↗

Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors.Semantic proximity Read ↗

Co-occurring genomic alterations and immunotherapy efficacy in NSCLCSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.